Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
D 50.77 6.08% 2.91
VCEL closed up 6.08 percent on Friday, May 14, 2021, on 45 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical VCEL trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 6.08%
Wide Bands Range Expansion 6.08%
Lower Bollinger Band Touch Weakness 6.08%
Oversold Stochastic Weakness 6.08%
180 Bearish Setup Bearish Swing Setup 7.56%
Older End-of-Day Signals for VCEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 3 days ago
Up 5% 3 days ago
Rose Above Previous Day's High 3 days ago
Up 3% 3 days ago
Up 2% 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Vericel Corporation Description

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cells Heart Failure Cell Therapy Knee Burns Myopathy Cardiomyopathy Cartilage Osteochondritis Dissecans Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.895
52 Week Low 12.82
Average Volume 900,467
200-Day Moving Average 33.88
50-Day Moving Average 53.90
20-Day Moving Average 56.32
10-Day Moving Average 52.91
Average True Range 3.62
ADX 29.05
+DI 17.53
-DI 26.05
Chandelier Exit (Long, 3 ATRs ) 54.03
Chandelier Exit (Short, 3 ATRs ) 57.01
Upper Bollinger Band 67.09
Lower Bollinger Band 45.55
Percent B (%b) 0.24
BandWidth 38.23
MACD Line -1.66
MACD Signal Line -0.18
MACD Histogram -1.481
Fundamentals Value
Market Cap 2.31 Billion
Num Shares 45.4 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio 16923.33
Price-to-Sales 9.59
Price-to-Book 9.99
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 55.87
Resistance 3 (R3) 55.36 53.16 55.02
Resistance 2 (R2) 53.16 51.86 53.41 54.74
Resistance 1 (R1) 51.96 51.06 52.56 52.47 54.45
Pivot Point 49.76 49.76 50.06 50.01 49.76
Support 1 (S1) 48.56 48.46 49.16 49.07 47.09
Support 2 (S2) 46.36 47.66 46.61 46.80
Support 3 (S3) 45.16 46.36 46.52
Support 4 (S4) 45.67